
Mediwound Ltd
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $7.68
- Today's High:
- $7.9
- Open Price:
- $7.68
- 52W Low:
- $7.1
- 52W High:
- $14.58
- Prev. Close:
- $7.67
- Volume:
- 13944
Company Statistics
- Market Cap.:
- $72.67 million
- Book Value:
- 4.816
- Revenue TTM:
- $25.99 million
- Operating Margin TTM:
- -34.12%
- Gross Profit TTM:
- $13.17 million
- Profit Margin:
- -55.53%
- Return on Assets TTM:
- -12.97%
- Return on Equity TTM:
- -88.29%
Company Profile
Mediwound Ltd had its IPO on 2014-03-20 under the ticker symbol MDWD.
The company operates in the Healthcare sector and Biotechnology industry. Mediwound Ltd has a staff strength of 83 employees.
Stock update
Shares of Mediwound Ltd opened at $7.68 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.68 - $7.9, and closed at $7.8.
This is a +1.69% increase from the previous day's closing price.
A total volume of 13,944 shares were traded at the close of the day’s session.
In the last one week, shares of Mediwound Ltd have slipped by -4.65%.
Mediwound Ltd's Key Ratios
Mediwound Ltd has a market cap of $72.67 million, indicating a price to book ratio of 31.7321 and a price to sales ratio of 2.4803.
In the last 12-months Mediwound Ltd’s revenue was $25.99 million with a gross profit of $13.17 million and an EBITDA of $-8166000. The EBITDA ratio measures Mediwound Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Mediwound Ltd’s operating margin was -34.12% while its return on assets stood at -12.97% with a return of equity of -88.29%.
In Q2, Mediwound Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 2.2%.
Mediwound Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -0.07
Its diluted EPS in the last 12-months stands at $-2.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.07. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Mediwound Ltd’s profitability.
Mediwound Ltd stock is trading at a EV to sales ratio of 1.7632 and a EV to EBITDA ratio of -2.5422. Its price to sales ratio in the trailing 12-months stood at 2.4803.
Mediwound Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $64.37 million
- Total Liabilities
- $8.31 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $1.07 million
- Dividend Payout Ratio
- 0%
Mediwound Ltd ended 2025 with $64.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $64.37 million while shareholder equity stood at $34.93 million.
Mediwound Ltd ended 2025 with $0 in deferred long-term liabilities, $8.31 million in other current liabilities, in common stock, $0 in retained earnings and $0 in goodwill. Its cash balance stood at $51.12 million and cash and short-term investments were $51.12 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Mediwound Ltd’s total current assets stands at $58.05 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $3.82 million compared to accounts payable of $3.53 million and inventory worth $3.11 million.
In 2025, Mediwound Ltd's operating cash flow was $0 while its capital expenditure stood at $1.07 million.
Comparatively, Mediwound Ltd paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $7.8
- 52-Week High
- $14.58
- 52-Week Low
- $7.1
- Analyst Target Price
- $27.25
Mediwound Ltd stock is currently trading at $7.8 per share. It touched a 52-week high of $14.58 and a 52-week low of $14.58. Analysts tracking the stock have a 12-month average target price of $27.25.
Its 50-day moving average was $9.17 and 200-day moving average was $10.92 The short ratio stood at 5.16 indicating a short percent outstanding of 0%.
Around 2423.7% of the company’s stock are held by insiders while 2960.9% are held by institutions.
Frequently Asked Questions About Mediwound Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.